Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

34 results

Page 1 of 2

Essential Evidence-Based Psychopharmacology
  • Essential Evidence-Based Psychopharmacology
  • 2nd edition
  • Edited by Dan Stein, Bernard Lerer, Stephen M. Stahl
  • Published online: 05 August 2012
  • Print publication: 05 July 2012
  • View description
    This volume presents up-to-date, comprehensive and high quality reviews of the psychopharmacological evidence-base for each of the major psychiatric disorders, written by expert psychopharmacologists from around the world. Building on the success of the first edition, the volume summarizes the wealth of new developments in the field and sets them within the context of day-to-day clinical practice. All chapters have been fully updated and new contributions on personality disorders and substance dependence added. Each chapter provides information about optimal first line pharmacological interventions, maintenance pharmacotherapy and the management of treatment-refractory patients. The content is organized according to the DSM-V listing of psychiatric disorders, and covers all major conditions including schizophrenia, mood disorders, anxiety disorders, eating disorders and Alzheimer's disorder. These issues lie at the heart of clinical psychopharmacology, making this book invaluable to all practising and trainee clinicians, in a mental health setting or a less specialised environment.
  • Interrelationship of Age, Depression, and Central Serotonergic Function: Evidence From Fenfluramine Challenge Studies
  • Bernard Lerer, Dan Gillon, Pesach Lichtenberg, Malka Gorfine, Yevgenia Gelfin, Baruch Shapira
  • Journal: International Psychogeriatrics / Volume 8 / Issue 1 / March 1996
  • Published online by Cambridge University Press: 07 January 2005, pp. 83-102
  • View abstract

    The purpose of this study was to examine the relationship between age-associated changes in central serotonergic function and abnormalities associated with major depression. Under randomized double-blind conditions, prolactin and cortisol responses to the serotonin-releasing agent d,l-fenfluramine hydrochloride (60 mg orally) and placebo were examined in 30 normal subjects (15 men, 15 women; age range 21–84 years) and 39 patients with major depressive disorder, endogenous subtype (14 men, 25 women; age range 29–72 years). In the normal subjects, a significant Age x Challenge x Time interaction was observed in the prolactin response (p = .03). This was primarily due to the elevated prolactin responses of the younger healthy women. Peak minus baseline (delta) prolactin responses were negatively correlated with age (women, p = .004; men, p = .06). In the depressed patients there was no age-related decline in prolactin response to fenfluramine. When depressed and healthy younger subjects were compared, delta prolactin responses to fenfluramine were significantly blunted in young patients with depression (p = .003) irrespective of the significant effect of gender (p = .01), but not in older depressed patients. Cortisol responses to fenfluramine did not reveal consistent effects of age, gender, or diagnosis. Age-related decline in central serotonergic function may make older individuals more vulnerable to depression and possibly render depressive episodes more frequent, more severe, and less amenable to treatment.

Pharmacogenetics of Psychotropic Drugs
  • Pharmacogenetics of Psychotropic Drugs
  • Edited by Bernard Lerer
  • Published online: 20 August 2009
  • Print publication: 29 August 2002
  • View description
    Pharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.
  • 1 - Genes and psychopharmacology: exploring the interface
  • from Part I - Introduction
    • By Bernard Lerer, Biological Psychiatry Laboratory, Department of Psychiatry, Hadassah–Hebrew University Medical Center, Jerusalem, Israel
  • Edited by Bernard Lerer, Hadassah-Hebrew Medical Center, Jerusalem
  • Book: Pharmacogenetics of Psychotropic Drugs
  • Published online: 20 August 2009
  • Print publication: 29 August 2002, pp 3-18
  • View abstract

    Summary

    This chapter serves as a general introduction to psychopharmacogenetics and to the topics covered in this book, which provides the researcher and clinician with an overview of the pivotal topics in psychopharmacogenetics. For much of its history, the focus of pharmacogenetics has been on drug-metabolizing enzymes. This was because of the availability of techniques to detect phenotypic differences between individuals in the plasma level of drugs and to study their genetic basis. The chapter focuses on the methodological issues in pharmacogenetic research design. The interface between psychopharmacology and molecular genetics is already a focus of considerable research activity and this is likely to intensify as anticipated technological advances provide the tools for even more sophisticated studies. It may take longer than originally thought, but ultimately pharmacogenetics and pharmacogenomics will revolutionize the field of clinical psychopharmacology and the development of psychotropic drugs.

Page 1 of 2